{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ENVX",
  "name": "Enovix Corporation",
  "url": "https://frontierpicks.com/dossiers/ENVX/",
  "json_url": "https://frontierpicks.com/dossiers/ENVX.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Enovix shares are more likely to lag the S&P 500 over three months after the company dropped smartphone field testing and guided fourth-quarter sales below the third quarter's on 12 November 2026. The fourth-quarter report, expected in late February 2027, shows whether drone orders carry the 2027 revenue guidance.",
  "invalidation_trigger": "A daily close above $2.53, the 2026-11-11 close before the third-quarter report, which would erase the post-results fall and show the shares leading; or Enovix announcing that a smartphone customer has resumed qualification of its AI-2 cell.",
  "catalyst_date": null,
  "portfolio": null,
  "pick": null,
  "themes": [
    "defense-aerospace"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Holders of record at the close on 2026-11-13 receive one warrant per four shares; the warrants are exercisable at $3.00 in cash or in 2028 notes at face value.",
    "The warrants expire on 2028-04-28, or earlier if the stock trades at or above $3.30 on 20 of any 30 consecutive trading days.",
    "Enovix has $232.0 million of 4.75% convertible notes due 2030 outstanding after its post-quarter repurchases, plus 3.00% convertible notes due 2028."
  ],
  "source_links": [
    {
      "title": "Enovix Corp - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001828318/000182831826000069/enovixq32026financialres.htm",
      "date": "2026-11-12"
    },
    {
      "title": "Earnings call transcript: Enovix Q3 2026 revenue beats, but stock sinks 21%",
      "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-enovix-q3-2026-revenue-beats-but-stock-sinks-21-93CH-5023035",
      "date": null
    },
    {
      "title": "Enovix Corp Reports Q3 Fiscal 2026 Revenue of $11.0 Million, Exceeding Estimates; GAAP Net Loss Per Share Improves to $0.19",
      "url": "https://www.gurufocus.com/news/9194545/enovix-corp-reports-q3-fiscal-2026-revenue-of-110-million-exceeding-estimates-gaap-net-loss-per-share-improves-to-019",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue was $11.0 million, up 38% from a year earlier; non-GAAP gross margin was a record 34.5%.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Enovix will not proceed with smartphone field testing after pre-AI-2 cells missed its target of more than 1,000 watt-hours per liter.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Fourth-quarter 2026 revenue guidance is $9.0–10.0 million; 2027 revenue guidance is $65–85 million.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Cash, equivalents, marketable securities and restricted cash were $512.2 million, or $2.35 per share, at 2026-10-04.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-10-04"
    },
    {
      "claim": "Non-GAAP free cash flow was negative $33.1 million in the third quarter and negative $100.8 million for the year to date.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-10-04"
    },
    {
      "claim": "Enovix retired $128 million face value of 2030 notes for about $81.4 million, leaving $232.0 million outstanding.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Enovix received a 100,000-battery order from a multinational dual-use drone systems provider, with deliveries from early 2027.",
      "source": "Enovix 8-K, third-quarter 2026 results",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Enovix cut about 220 of 946 positions, which it expects to save about $8.5 million a year.",
      "source": "Enovix 8-K, Regulation FD disclosure",
      "as_of": "2026-11-05"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Industrials",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-10-04",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-10-04",
              "filed": "2026-11-13",
              "value_musd": 11,
              "yoy_pct": 38.2
            },
            {
              "end": "2026-07-05",
              "filed": "2026-08-12",
              "value_musd": 9,
              "yoy_pct": 20.8
            },
            {
              "end": "2026-04-05",
              "filed": "2026-05-14",
              "value_musd": 7.6,
              "yoy_pct": 49.1
            },
            {
              "end": "2025-12-28",
              "filed": "2026-02-25",
              "value_musd": 11.3,
              "yoy_pct": 15.9
            },
            {
              "end": "2025-09-28",
              "filed": "2026-11-13",
              "value_musd": 8,
              "yoy_pct": 85.1
            },
            {
              "end": "2025-06-29",
              "filed": "2026-08-12",
              "value_musd": 7.5,
              "yoy_pct": 98.2
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-10-04",
              "filed": "2026-11-13",
              "pct": 30.1
            },
            {
              "end": "2026-07-05",
              "filed": "2026-08-12",
              "pct": 14.4
            },
            {
              "end": "2026-04-05",
              "filed": "2026-05-14",
              "pct": 20.4
            },
            {
              "end": "2025-12-28",
              "filed": "2026-02-25",
              "pct": 22.2
            },
            {
              "end": "2025-09-28",
              "filed": "2026-11-13",
              "pct": 17.5
            },
            {
              "end": "2025-06-29",
              "filed": "2026-08-12",
              "pct": 26
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-10-04",
              "filed": "2026-11-13",
              "pct": -356
            },
            {
              "end": "2026-07-05",
              "filed": "2026-08-12",
              "pct": -479.8
            },
            {
              "end": "2026-04-05",
              "filed": "2026-05-14",
              "pct": -577.6
            },
            {
              "end": "2025-12-28",
              "filed": "2026-02-25",
              "pct": -390.5
            },
            {
              "end": "2025-09-28",
              "filed": "2026-11-13",
              "pct": -587.9
            },
            {
              "end": "2025-06-29",
              "filed": "2026-08-12",
              "pct": -585.6
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": -42.1
        },
        "net_income": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "four_quarters_end": "2026-10-04",
          "value_musd": -41.9,
          "four_quarters_musd": -158.3
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "first_end": "2025-12-28",
          "value_musd": -111.1
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "first_end": "2025-12-28",
          "value_musd": 17.7
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "first_end": "2025-12-28",
          "value_musd": -128.8
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "base_end": "2025-09-28",
          "pct": 6.2
        },
        "cash": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 405.5
        },
        "debt": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 533.5,
          "composition": "non-current long-term debt plus current debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": -128
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 1.3,
          "yoy_pct": -83.8
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 4.3
        },
        "inventory": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 19.8
        },
        "equity": {
          "status": "ok",
          "end": "2026-10-04",
          "filed": "2026-11-13",
          "value_musd": 169.1
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-11-06",
          "basis_filed": "2026-11-13",
          "value_musd": 339.5
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-11-06",
          "basis_filed": "2026-11-13",
          "value_musd": 467.6
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-11-06",
          "basis_filed": "2026-11-13",
          "multiple": 12
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-11-06",
          "basis_filed": "2026-11-13",
          "multiple": 2
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-11-06",
          "basis_filed": "2026-11-13",
          "pct": -37.9
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-11-13",
      "short_pct_of_outstanding": 27.08,
      "days_to_cover": 6.8,
      "change_pct": 8.3
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-14",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-17",
          "bought_usd": 0,
          "sold_usd": 0,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-15",
          "bought_usd": 0,
          "sold_usd": 16783.76,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\nEnovix shares are more likely to lag the S&P 500 over the next three months. On 2026-11-12 the company dropped smartphone field testing, its largest long-term market, and guided fourth-quarter sales below the third quarter's. Growth now depends on drone and smart-eyewear orders that ship from early 2027. The fourth-quarter report, expected in late February 2027, is the first to show whether those orders support the 2027 revenue guidance.\n\nThe third quarter itself was better than expected. Revenue was $11.0 million, up 38% from a year earlier and 22% from the previous quarter, and the non-GAAP gross margin reached a record 34.5% (company 8-K, 2026-11-12). The smartphone decision came with the same report. Enovix said its pre-AI-2 cells missed its latest energy-density target of more than 1,000 watt-hours per liter. The shares fell from a $2.53 close on 2026-11-11 to $1.80 on 2026-11-12, a new 52-week closing low.\n\nAt the $1.80 close, the market prices Enovix below its cash. The company reported $512.2 million of cash, equivalents, marketable securities and restricted cash at 2026-10-04, or $2.35 per share (8-K, 2026-11-12). That discount reflects continuing losses: non-GAAP free cash flow was negative $100.8 million for the first three quarters of 2026. It also reflects $232.0 million of 4.75% 2030 notes still outstanding, plus the 3.00% 2028 notes.\n\n## Bull Case\n- **Cash exceeds the market value.** Gross cash and securities of $2.35 per share at 2026-10-04 (8-K, 2026-11-12) sit above the $1.80 close of 2026-11-12, before netting out debt.\n- **Debt retired at a discount.** After quarter end, Enovix retired $128 million face value of its 2030 notes for about $81.4 million, a 36% discount that cut debt by $46.6 million more than the cash paid (8-K, 2026-11-12).\n- **Drone orders are real purchase orders.** Enovix received a 100,000-battery order from a multinational dual-use drone maker and a first production order for its MX1-B01 silicon-blend cell from a US drone maker, with deliveries from early 2027 (8-K, 2026-11-12).\n- **2027 guidance implies doubling sales.** Revenue guidance for 2027 is $65–85 million, against an estimated $36.7–37.7 million for 2026 (8-K, 2026-11-12). Management put backlog at about $37 million on the 2026-11-12 call.\n- **Costs are coming down.** Enovix announced 220 job cuts on 2026-11-05, which it expects to save about $8.5 million a year, and a $19 million expansion to double drone battery capacity in South Korea by the second quarter of 2027.\n\n## Bear Case\n- **Smartphone path is on hold.** On 2026-11-12 Enovix said it will not proceed with smartphone field testing and that 2027 guidance assumes nominal or no smartphone revenue. On the call, management said restarting with a second customer would take roughly six to eight months.\n- **Sales step down next quarter.** Fourth-quarter revenue guidance is $9.0–10.0 million, below the third quarter's $11.0 million, with a non-GAAP loss of $0.13–0.17 per share (8-K, 2026-11-12).\n- **2027 midpoint trails estimates.** The $75 million midpoint of 2027 sales guidance is below the $77.834 million consensus estimate reported alongside the 2026-11-12 release.\n- **Losses continue.** The third-quarter GAAP net loss was $41.9 million, or $0.19 per share. Non-GAAP free cash flow was negative $33.1 million for the quarter (8-K, 2026-11-12).\n- **Leadership and legal overhang.** The CEO is serving on an interim basis, according to SEC Form 4 filings. The chief legal officer's departure was disclosed on 2026-11-04. Block & Leviton announced an investigation of possible securities-law violations on 2026-11-12.\n- **Warrant supply caps rallies.** The new warrants are exercisable at $3.00 and expire early if the stock trades at or above $3.30 on 20 of 30 consecutive trading days (8-K, 2026-11-12). Exercise adds shares exactly when the price recovers.\n\n## Setup & Price Structure\nThe shares closed at $1.80 on 2026-11-12, the 52-week closing low. That is 80.4% below the 52-week intraday high of $9.19 set on 2025-12-10. The 3-month change is −58.9%, measured from a $4.39 close on 2026-08-14.\n\nOn adjusted daily closes, the last close sits well below the 50-day moving average of $2.82 and the 200-day moving average of $4.93, both as of 2026-11-12. The levels the case turns on are the $2.53 close of 2026-11-11, the last price before the third-quarter report, and the 50-day average. The shares briefly rose from $2.40 on 2026-11-05 to $2.76 on 2026-11-06 after the cost-cut and drone-order announcements. The 2026-11-12 report wiped out that gain.\n\n## Catalyst Calendar\n\n- **~2026-11-18 (est.):** Distribution of warrants to shareholders, expected to trade on Nasdaq as ENVXW. Sets how many new shares can come from exercise at $3.00 and how much of the 2028 notes can be retired through the warrants.\n- **~2027-01-15 (est.):** First deliveries of the 100,000-battery dual-use drone order, scheduled for January 2027. Shows whether drone orders are turning into the revenue that 2027 guidance relies on.\n- **~2027-02-25 (est.):** Fourth-quarter 2026 report and 2027 cost outlook. Shows whether fourth-quarter sales meet the $9.0–10.0 million guidance and how much cash 2027 will consume.\n\n## What Would Change Our Mind\n\nA daily close above $2.53, the 2026-11-11 close before the third-quarter report, which would erase the post-results fall and show the shares leading; or Enovix announcing that a smartphone customer has resumed qualification of its AI-2 cell.\n\n## Correlation Notes\nEnovix trades on its own news: technology milestones, customer orders and financing actions. Broad market moves have less effect. Its 2027 revenue now depends mostly on drone and defense demand, so purchase orders and procurement news from drone makers carry more weight than consumer-electronics cycles. The warrant distribution and note repurchases can move the share count and the debt load independently of operating results.",
  "first_seen": "2026-11-12",
  "last_analyzed": "2026-11-13T03:38:08+00:00",
  "last_synthesized": "2026-11-13",
  "date_modified": "2026-11-13",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}